OriGene Technologies Acquires Beijing Zhongshan Golden Bridge Biotechnology

OriGene Technologies, Inc. announced today the acquisition of Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd (ZsBio).

Founded in the year 1993, ZsBio provides testing products (pathology) within their domestic Chinese market, such as oncology diagnostics.

OriGene had the following to say regarding today’s acquisition, “With its leadership position in the Chinese pathology testing market, ZsBio is the ideal partner for OriGene,” said Wei-Wu He, CEO of OriGene.  “ZsBio is already a leader in pathology products for cancer applications and has a wide range of market-leading diagnostics products used in hospitals and laboratories in China. In turn, OriGene brings to ZsBio innovative highly specific monoclonal antibodies and assays to complement and strengthen ZsBio’s portfolio of products.”

In a market that has experienced double-digit market growth annually, OriGene hopes the acquisition of ZsBio bolsters their bottom-line.

OriGene Technologies, Inc., is a biosciences company dedicated to develop gene centric innovative products and services to improve the quality of healthcare diagnostics and treatments while ZsBio has more than 25 years of pathology diagnostics experience in China.



Latest News

Aigen Investment Management LP Sells 6,456 Shares of TopBuild Corp
Aigen Investment Management LP Sells 6,456 Shares of TopBuild Corp
Cae Inc  Stake Increased by Swiss National Bank
Cae Inc Stake Increased by Swiss National Bank
Fiera Capital Corp Makes New $224,000 Investment in Trane
Fiera Capital Corp Makes New $224,000 Investment in Trane
Cetera Investment Advisers Boosts Holdings in Johnson & Johnson
Cetera Investment Advisers Boosts Holdings in Johnson & Johnson
Cetera Advisors LLC Decreases Stock Position in Johnson & Johnson
Cetera Advisors LLC Decreases Stock Position in Johnson & Johnson
Russell Investments Group Ltd. Sells 40,194 Shares of WesBanco Inc
Russell Investments Group Ltd. Sells 40,194 Shares of WesBanco Inc


© 2006-2020 Ticker Report